Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 13:2014:194123.
doi: 10.1155/2014/194123. eCollection 2014.

PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors

Martina Sollini  1 , Paola Anna Erba  2 , Alessandro Fraternali  1 , Massimiliano Casali  1 , Maria Liberata Di Paolo  1 , Armando Froio  1 , Andrea Frasoldati  3 , Annibale Versari  1
Affiliations

PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors

Martina Sollini et al. ScientificWorldJournal. .

Abstract

Somatostatin (SST) is a 28-amino-acid cyclic neuropeptide mainly secreted by neurons and endocrine cells. A major interest for SST receptors (SSTR) as target for in vivo diagnostic and therapeutic purposes was born since a series of stable synthetic SST-analouges PET became available, being the native somatostatin non feasible for clinical use due to the very low metabolic stability. The rationale for the employment of SST-analogues to image cancer is both based on the expression of SSTR by tumor and on the high affinity of these compounds for SSTR. The primary indication of SST-analogues imaging is for neuroendocrine tumors (NETs), which usually express a high density of SSTR, so they can be effectively targeted and visualized with radiolabeled SST-analogues in vivo. Particularly, SST-analogues imaging has been widely employed in gastroenteropancreatic (GEP) NETs. Nevertheless, a variety of tumors other than NETs expresses SSTR thus SST-analogues imaging can also be used in these tumors, particularly if treatment with radiolabeled therapeutic SST-analouges PET is being considered. The aim of this paper is to provide a concise overview of the role of positron emission tomography/computed tomography (PET/CT) with (68)Ga-radiolabeled SST-analouges PET in tumors other than GEP-NETs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
68Ga-DOTATOC PET/CT images (MIP, sagittal, axial) in a patient with metastatic paraganglioma.
Figure 2
Figure 2
68Ga-DOTATOC PET/CT images (MIP, axial) in a patient affected by metastatic phaeocromochytoma.
Figure 3
Figure 3
68Ga-DOTATATE PET/CT images (MIP, axial) in a case of metastatic atypical lung carcinoid.
Figure 4
Figure 4
68Ga-DOTATOC PET/CT images (MIP, sagittal) in a patient with metastatic small cell lung carcinoma.
Figure 5
Figure 5
68Ga-DOTATATE PET/CT images (MIP, coronal, sagittal, and axial) in a patient with meningioma.
Figure 6
Figure 6
68Ga-DOTATATE PET/CT images (MIP, axial) in a patient affected by metastatic medullary thyroid carcinoma.
Figure 7
Figure 7
68Ga-DOTATATE PET/CT images (MIP, axial) in a patient with metastatic iodine-negative differentiated thyroid carcinoma.
Figure 8
Figure 8
68Ga-DOTATATE PET/CT images (MIP, axial) in a patient with thymoma.
Figure 9
Figure 9
68Ga-DOTATOC PET/CT images (MIP, axial) in a patient with metastatic breast cancer.
Figure 10
Figure 10
68Ga-DOTATATE PET/CT images (MIP, axial) in a patient with non-Hodgkin lymphoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Reviews. 2003;24(4):389–427. - PubMed
    1. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging. 2003;30(5):781–793. - PubMed
    1. Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Annals of Oncology. 2001;12(2):S51–S61. - PubMed
    1. Olsen JO, Pozderac RV, Hinkle G, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (OctreoScan) Seminars in Nuclear Medicine. 1995;25(3):251–261. - PubMed
    1. Briganti V, Sestini R, Orlando C, et al. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clinical Cancer Research. 1997;3(12):2385–2391. - PubMed

MeSH terms